Palisade Bio (PALI)
Develops a once-daily oral PDE4 prodrug for ulcerative colitis and Crohn's disease.
Something off on this page? Send us feedback.
Develops PALI-2108, a once-daily oral PDE4 inhibitor prodrug intended for bacterial activation in the terminal ileum and colon for inflammatory bowel disease. With no approved products or product revenue, it operates as a clinical sponsor reliant on third parties and a Giiant license.
Develops PALI-2108, a once-daily oral PDE4 inhibitor prodrug for ulcerative colitis and Crohn's disease, designed for bacterial activation in the terminal ileum and colon. The approach aims to sustain local target inhibition while limiting systemic exposure and improving tolerability.
Operates as a lean clinical-stage sponsor, using consultants and relying on contract research organizations and other third parties to conduct and oversee trials. It holds worldwide rights to PALI-2108 and PALI-1908 from Giiant, with development, manufacturing, milestone and royalty obligations under the license.
Maintains no physical headquarters and has no approved products or product revenue. Future revenue depends on regulatory approval, product marketing, out-licensing or sublicensing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jul 23, 2026 | Oppenheimer | Initiate | Outperform | |
| Jun 30, 2026 | H.C. Wainwright | Reiterate | Buy | $2 |
| Jun 30, 2026 | Oppenheimer | Target | $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $125.2M · Total debt $0 · Total assets $127.3M · Shareholders' equity $121.7M
- Revenue
- $500.0K
- Operating income
- −$11.7M
- Net income
- −$10.6M
No dividends on record.
| Institutions95 holders · as of Mar 31, 2026 | 85.78% | 149.49M shares | |
| Insiders6 holders · as of Aug 21, 2026 | 1.34% | 2.34M shares | |
| Otherremainder | 12.88% | 22.45M shares |
174.27M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ameriprise Financial IncInstitution | 6.60% | 11.51M | 13Fas of Mar 31, 2026 |
B Group, Inc.Institution | 6.55% | 11.41M | 13Fas of Mar 31, 2026 |
Janus Henderson Group PLCInstitution | 6.13% | 10.69M | 13Fas of Mar 31, 2026 |
Octagon Capital Advisors LPInstitution | 5.90% | 10.28M | 13Fas of Mar 31, 2026 |
Soleus Capital Master Fund, L.P.Institution | 5.37% | 9.35M | 13Gfiled May 27, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 8, 2026 | Robert Jr. Baltera | director | +20,000 | $1.99 |
| Jul 9, 2026 | Robert Jr. Baltera | director | +25,000 | $1.96 |
| Jul 7, 2026 | John David Finley | director, officer: CEO, CFO | −146,798 | $2.07 |
| Jul 7, 2026 | Mitchell Lawrence Jones | officer: Chief Medical Officer | −51,880 | $2.05 |
| Jul 6, 2026 | Robert Jr. Baltera | director | +20,000 | $2.05 |
- AbbVie
The broadest approved UC/CD overlap through Skyrizi, Rinvoq and Humira.
- Johnson & Johnson
Multiple biologics address the same moderate-to-severe UC/CD treatment pool.
- Takeda (ADR)
Entyvio is an established gut-focused UC/CD biologic for the same patients.
- Eli Lilly
Omvoh brings an IL-23 option across moderate-to-severe UC and CD.
- Pfizer
Oral Velsipity and Xeljanz address moderate-to-severe UC.
- Bristol-Myers Squibb
Once-daily oral Zeposia addresses moderate-to-severe UC.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Palisade Bio | $2.00 | +1.79% | $345.4M | — | — | 690.8 | — |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Johnson & Johnson | $275.21 | −0.01% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Takeda (ADR) | $18.51 | +0.38% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Bristol-Myers Squibb | $67.88 | +0.34% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 38.6 | 20.2 | 4.8 | +6.2% |